Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 11/11/2018 |
| Start Date: | September 12, 2007 |
| End Date: | May 2, 2018 |
Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers
This trial studies how well cardiac biomarkers work in the early detection of cardiotoxicity
in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are
known to cause damage to heart muscle cells, resulting in heart failure. Often, the damage is
not detected until heart failure has already occurred. Testing for cardiac biomarkers, such
as troponin I and/or T and B-type natriuretic peptide (BNP), may be useful in detecting heart
damage earlier than other tests currently performed (such as echocardiogram and
electrocardiogram).
in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are
known to cause damage to heart muscle cells, resulting in heart failure. Often, the damage is
not detected until heart failure has already occurred. Testing for cardiac biomarkers, such
as troponin I and/or T and B-type natriuretic peptide (BNP), may be useful in detecting heart
damage earlier than other tests currently performed (such as echocardiogram and
electrocardiogram).
PRIMARY OBJECTIVES:
I. To determine if specific biomarkers (troponin I and B-type natriuretic peptide [BNP])
detect cardiotoxicity earlier than standard clinical means in patients receiving sunitinib
malate (SU11248) or sorafenib chemotherapy.
SECONDARY OBJECTIVES:
I. To prospectively evaluate the incidence and severity of cardiac toxicity related to
sunitinib or sorafenib during chemotherapy.
OUTLINE:
Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2
weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
I. To determine if specific biomarkers (troponin I and B-type natriuretic peptide [BNP])
detect cardiotoxicity earlier than standard clinical means in patients receiving sunitinib
malate (SU11248) or sorafenib chemotherapy.
SECONDARY OBJECTIVES:
I. To prospectively evaluate the incidence and severity of cardiac toxicity related to
sunitinib or sorafenib during chemotherapy.
OUTLINE:
Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2
weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
Inclusion Criteria:
- Starting a new course of chemotherapy at MD Anderson Cancer Center that includes
sunitinib or sorafenib
- Has a life expectancy of greater than 6 months
Exclusion Criteria:
- Unstable angina within the last 3 months
- Myocardial infarction within the last 3 months
- Left ventricular ejection fraction (LVEF) less than 40%
- Decompensated heart failure (HF) in the last 3 months
We found this trial at
1
site
Click here to add this to my saved trials
